禮來(LLY.US)「塞普替尼片」在中國獲批上市

智通財經

昨天

【禮來(LLY.US)「塞普替尼片」在中國獲批上市】智通財經APP獲悉，9月18日，NMPA官網顯示，禮來製藥(LLY.US) 5.1 類新藥「塞普替尼片」在國內獲批上市。公開資料顯示，這是塞普替尼片劑劑型首次在國內獲批。塞普替尼(Selpercatinib)是一種同類首創，高選擇性和抑制活性的小分子 RET 抑制劑，具有中樞神經系統(CNS)活性，可抑制多種RET變異。該藥是全球首款獲批的高選擇性 RET 抑制劑，通過抑制異常 RET 激酶的活性而發揮作用。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/news/2668926243"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2668926243\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2668926243?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-09-18 21:13","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2668926243","market":"us","top_or_hot":-1,"title":"禮來(LLY.US)「塞普替尼片」在中國獲批上市","media":"智通財經","content":"<html><body><div>\n<div>\n<b>【禮來(LLY.US)「塞普替尼片」在中國獲批上市】</b>智通財經APP獲悉，9月18日，NMPA官網顯示，禮來製藥(LLY.US) 5.1 \n\n類新藥「塞普替尼片」在國內獲批上市。公開資料顯示，這是塞普替尼片劑劑型首次在國內獲批。塞普替尼(Selpercatinib)是一種同類首創，高選擇性和抑制活性的小分子 \n\nRET 抑制劑，具有中樞神經系統(CNS)活性，可抑制多種RET變異。該藥是全球首款獲批的高選擇性 RET 抑制劑，通過抑制異常 RET \n\n激酶的活性而發揮作用。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>禮來(LLY.US)「塞普替尼片」在中國獲批上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n禮來(LLY.US)「塞普替尼片」在中國獲批上市\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2026-09-18 21:13</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【禮來(LLY.US)「塞普替尼片」在中國獲批上市】</b>智通財經APP獲悉，9月18日，NMPA官網顯示，禮來製藥(LLY.US) 5.1 \n\n類新藥「塞普替尼片」在國內獲批上市。公開資料顯示，這是塞普替尼片劑劑型首次在國內獲批。塞普替尼(Selpercatinib)是一種同類首創，高選擇性和抑制活性的小分子 \n\nRET 抑制劑，具有中樞神經系統(CNS)活性，可抑制多種RET變異。該藥是全球首款獲批的高選擇性 RET 抑制劑，通過抑制異常 RET \n\n激酶的活性而發揮作用。                </div>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2668926243","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2668926243","pubTimestamp":1789737235,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【禮來(LLY.US)「塞普替尼片」在中國獲批上市】智通財經APP獲悉，9月18日，NMPA官網顯示，禮來製藥(LLY.US) 5.1 \n\n類新藥「塞普替尼片」在國內獲批上市。公開資料顯示，這是塞普替","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IPOS":"Renaissance International IPO ETF"},"translate_title":"Eli Lilly (LLY.US) \"Septinib Tablets\" Approved for Listing in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1.5},"content_text":"【禮來(LLY.US)「塞普替尼片」在中國獲批上市】智通財經APP獲悉，9月18日，NMPA官網顯示，禮來製藥(LLY.US) 5.1 \n\n類新藥「塞普替尼片」在國內獲批上市。公開資料顯示，這是塞普替尼片劑劑型首次在國內獲批。塞普替尼(Selpercatinib)是一種同類首創，高選擇性和抑制活性的小分子 \n\nRET 抑制劑，具有中樞神經系統(CNS)活性，可抑制多種RET變異。該藥是全球首款獲批的高選擇性 RET 抑制劑，通過抑制異常 RET \n\n激酶的活性而發揮作用。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}